Key Takeaways:
SBP Group's subsidiary Chia Tai Tianqing announced positive results from two clinical trials for its innovative cancer drug, M701, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
"M701 is expected to replace simple paracentesis drainage and conventional intraperitoneal chemotherapy infusion, becoming a standard treatment option," the company stated in its announcement.
The announcement included data from a Phase III study in malignant ascites (MA) and a Phase II study in malignant pleural effusion (MPE). In the Phase III trial, the "CD3/EpCAM bispecific antibody" significantly prolonged puncture-free survival and improved quality of life for patients with advanced gastric, colorectal, and ovarian cancer. The Phase II study showed it was an efficient and low-toxicity option for non-small cell lung cancer patients resistant to platinum-based chemotherapy.
The company's marketing application for M701 was accepted by China's Center for Drug Evaluation (CDE) in May. Approval would position M701 as the first standard treatment in China for malignant pleural and peritoneal effusions, potentially creating a significant new revenue stream for SBP Group.
The company highlighted that M701 demonstrated superior safety and practical clinical accessibility compared to catumaxomab, which is approved in the European Union. Against existing methods like paracentesis drainage, M701 showed higher response rates and more durable control of effusion.
This positive data from two separate trials strengthens the drug's profile ahead of a final regulatory decision. Investors will be closely watching the CDE's review for the final approval, which could establish M701 as a first-in-class treatment in a key market.
This article is for informational purposes only and does not constitute investment advice.
